Colon cancer remains a leading cause of cancer related morbidity and mortality, both in the US and around the world. Many therapeutic agents and their combinations are being used to inhibit the growth and metastasis of the tumor. However, a couple of significant problems with these strategies are the development of resistance to the drugs and the increased side effects of the drugs. A critical reason for the drug resistance is that directly or indirectly targeted therapeutics through various kinase pathways, they activate the pregnane X receptor (PXR). Hence, novel targeted therapeutics is essential that suppress specific pathways but do not induce PXR. In this regard, we have developed a novel drug MRLTHB and water-soluble analog MRLTHBCD, which inhibits Notch-1 signaling and does not induce PXR. The goal of the current project is to further characterize the drug and generate preclinical data as an oral therapeutic both alone and in combination with 5-fluorouracil (5-FU) for colon cancer. In previous studies, we have determined that downregulating Doublecortin calmodulin-like kinase 1 (DCLK1) suppresses colon cancer xenograft growth, suggesting that targeting DCLK1 would be an efficient strategy for colon cancers. We have now determined that THB and THBCD specifically inhibit DCLK1 kinase activity and but do not affect the kinase activity calmodulin like kinases CAMKII and CAMKIV. In addition, we have determined that the compounds inhibit the growth of colon cancer cells in a novel culture method that we have developed termed """"""""Tumor in a Dish"""""""" (TiD) where cancer cells are grown in a three-dimensional culture that includes normal epithelial cells, fibroblasts and endothelial cells. The model creates an in vivo-like tumor microenvironment that provides the necessary cell-cell contact, 3D-architecture, and the influence of different cell types. The observed selective killing of cancer cells in this system suggests that the compounds are highly specific and have good potency. Mechanistically, we have determined that the compounds inhibit the Notch signaling pathway and PXR expression. Based on our preliminary studies, DCLK1 targeting by THB and THBCD resulting in suppression of both Notch signaling and PXR is a valid therapeutic strategy for colon cancers.
We aim to continue developing preclinical data in the current application.
In aim 1, we propose to determine the role of Notch-1 in PXR expression.
In aim 2, we will perform detailed PK/PD studies of the compound and find the optimal dose to perform preclinical studies in xenotransplant and APCmin/+ mouse models.
In aim 3, we propose then to continue and determine the effect of the combination of THB and THBCD with 5-fluorouracil to inhibit colon cancer growth. Effect of the compounds on Akt phosphorylation, Notch-1 activation, and DCLK1 and PXR expression in the tumor will be determined. These proposed studies would provide compelling mechanistic evidence for initiating clinical trials for the novel compounds alone and in combination. These studies will also aid in optimizing a targeted chemotherapeutic regimen and identify novel biomarkers for the future clinical studies.

Public Health Relevance

Colon cancer is a major cause of cancer morbidity and mortality in the United States, and current therapeutics are highly toxicity. In this application, e have developed a new compound, and propose to perform a pre-clinical drug toxicity, PK/PD and biomarker studies of the compounds, and determine therapeutic efficacy alone and in combination with 5-Fluorouracil. The proposed studies will lead to developing strategies and identifying biomarkers for future clinical studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA182872-01
Application #
8627820
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Alley, Michael C
Project Start
2014-01-01
Project End
2018-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
1
Fiscal Year
2014
Total Cost
$511,692
Indirect Cost
$172,823
Name
University of Kansas
Department
Physiology
Type
Schools of Medicine
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
New, Jacob; Arnold, Levi; Ananth, Megha et al. (2017) Secretory Autophagy in Cancer-Associated Fibroblasts Promotes Head and Neck Cancer Progression and Offers a Novel Therapeutic Target. Cancer Res 77:6679-6691
Spaw, Mark; Anant, Shrikant; Thomas, Sufi Mary (2017) Stromal contributions to the carcinogenic process. Mol Carcinog 56:1199-1213
Subramaniam, Dharmalingam; Kaushik, Gaurav; Dandawate, Prasad et al. (2017) Targeting cancer stem cells for chemoprevention of pancreatic cancer. Curr Med Chem :
Angulo, Pablo; Kaushik, Gaurav; Subramaniam, Dharmalingam et al. (2017) Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy. J Hematol Oncol 10:10
Dandawate, Prasad R; Subramaniam, Dharmalingam; Jensen, Roy A et al. (2016) Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy. Semin Cancer Biol 40-41:192-208
Ponnurangam, Sivapriya; Dandawate, Prasad R; Dhar, Animesh et al. (2016) Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells. Oncotarget 7:3217-32
Venugopal, Anand; Subramaniam, Dharmalingam; Balmaceda, Julia et al. (2016) RNA binding protein RBM3 increases ?-catenin signaling to increase stem cell characteristics in colorectal cancer cells. Mol Carcinog 55:1503-1516
Dandawate, Prasad R; Subramaniam, Dharmalingam; Padhye, Subhash B et al. (2016) Bitter melon: a panacea for inflammation and cancer. Chin J Nat Med 14:81-100
Rangarajan, Parthasarathy; Subramaniam, Dharmalingam; Paul, Santanu et al. (2015) Crocetinic acid inhibits hedgehog signaling to inhibit pancreatic cancer stem cells. Oncotarget 6:27661-73
Ramalingam, Satish; Subramaniam, Dharmalingam; Anant, Shrikant (2015) Manipulating miRNA Expression: A Novel Approach for Colon Cancer Prevention and Chemotherapy. Curr Pharmacol Rep 1:141-153

Showing the most recent 10 out of 14 publications